A Matrix-based Model Predicts Primary Response to Infliximab in Crohn’s Disease

Thomas Billiet(KU Leuven), Séverine Vermeire(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Gert Van Assche(KU Leuven), Magali de Bruyn(KU Leuven), Sharat Singh(Mirati Therapeutics (United States)), Isabelle Cleynen(Universidad Carlos III de Madrid), Konstantinos Papamichael(Beth Israel Deaconess Medical Center), Fred Princen(Prometheus Biosciences (United States))
Journal of Crohn s and Colitis
September 7, 2015
10.1093/ecco-jcc/jjv156
Cited by 71

Related Papers

Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k